TY - JOUR
T1 - Loss of KMT2C reprograms the epigenomic landscape in hPSCs resulting in NODAL overexpression and a failure of hemogenic endothelium specification
AU - Maurya, Shailendra
AU - Yang, Wei
AU - Tamai, Minori
AU - Zhang, Qiang
AU - Erdmann-Gilmore, Petra
AU - Bystry, Amelia
AU - Martins Rodrigues, Fernanda
AU - Valentine, Mark C.
AU - Wong, Wing H.
AU - Townsend, Reid
AU - Druley, Todd E.
N1 - Funding Information:
The authors would like to thank Samantha Morris, Ph.D.; Christopher Sturgeon, Ph.D.; Thor Theunissen, Ph.D. and Maggie Ferris, M.D., Ph.D., with helpful discussions surrounding development of this manuscript. The expert technical assistance of Yiling Mi and Rose Connors is gratefully acknowledged. The deep-scale proteomic experiments were performed at the Washington University Proteomics Shared Resource (WU-PSR), R. Reid Townsend, Director. The WU-PSR is supported in part by the WU Institute of Clinical and Translational Sciences (NCATS UL1 TR000448), the Mass Spectrometry Research Resource (NIGMS P41 GM103422) and the Siteman Comprehensive Cancer Center Support Grant (NCI P30 CA091842). We would also like to thank Suellen Greco, D.V.M., Ph.D., and Washington University’s Division of Comparative Medicine as well as Jessica Hoisington-Lopez and the Edison Family Center of Genome Sciences and Systems Biology’s Sequencing and Innovation Laboratory for assistance with data generation. Support for this project was provided by the Eli Seth Matthews Leukemia Foundation and the Kellsie’s Hope Foundation to TED.
Funding Information:
This work was supported by the National Cancer Institute [P30 CA091842]; National Institute of General Medical Sciences [P41 GM103422]; Eli Seth Matthews Leukemia Foundation; Kellsie?s Hope Foundation; Institute for Clinical and Translational Research, Washington University School of Medicine (US) [NCATS UL1 TR000448]. The authors would like to thank Samantha Morris, Ph.D.; Christopher Sturgeon, Ph.D.; Thor Theunissen, Ph.D. and Maggie Ferris, M.D., Ph.D., with helpful discussions surrounding development of this manuscript. The expert technical assistance of Yiling Mi and Rose Connors is gratefully acknowledged. The deep-scale proteomic experiments were performed at the Washington University Proteomics Shared Resource (WU-PSR), R. Reid Townsend, Director. The WU-PSR is supported in part by the WU Institute of Clinical and Translational Sciences (NCATS UL1 TR000448), the Mass Spectrometry Research Resource (NIGMS P41 GM103422) and the Siteman Comprehensive Cancer Center Support Grant (NCI P30 CA091842). We would also like to thank Suellen Greco, D.V.M., Ph.D., and Washington University?s Division of Comparative Medicine as well as Jessica Hoisington-Lopez and the Edison Family Center of Genome Sciences and Systems Biology?s Sequencing and Innovation Laboratory for assistance with data generation. Support for this project was provided by the Eli Seth Matthews Leukemia Foundation and the Kellsie?s Hope Foundation to TED.
Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Germline or somatic variation in the family of KMT2 lysine methyltransferases have been associated with a variety of congenital disorders and cancers. Notably, KMT2A-fusions are prevalent in 70% of infant leukaemias but fail to phenocopy short latency leukaemogenesis in mammalian models, suggesting additional factors are necessary for transformation. Given the lack of additional somatic mutation, the role of epigenetic regulation in cell specification, and our prior results of germline KMT2C variation in infant leukaemia patients, we hypothesized that germline dysfunction of KMT2C altered haematopoietic specification. In isogenic KMT2C KO hPSCs, we found genome-wide differences in histone modifications at active and poised enhancers, leading to gene expression profiles akin to mesendoderm rather than mesoderm highlighted by a significant increase in NODAL expression and WNT inhibition, ultimately resulting in a lack of in vitro hemogenic endothelium specification. These unbiased multi-omic results provide new evidence for germline mechanisms increasing risk of early leukaemogenesis.
AB - Germline or somatic variation in the family of KMT2 lysine methyltransferases have been associated with a variety of congenital disorders and cancers. Notably, KMT2A-fusions are prevalent in 70% of infant leukaemias but fail to phenocopy short latency leukaemogenesis in mammalian models, suggesting additional factors are necessary for transformation. Given the lack of additional somatic mutation, the role of epigenetic regulation in cell specification, and our prior results of germline KMT2C variation in infant leukaemia patients, we hypothesized that germline dysfunction of KMT2C altered haematopoietic specification. In isogenic KMT2C KO hPSCs, we found genome-wide differences in histone modifications at active and poised enhancers, leading to gene expression profiles akin to mesendoderm rather than mesoderm highlighted by a significant increase in NODAL expression and WNT inhibition, ultimately resulting in a lack of in vitro hemogenic endothelium specification. These unbiased multi-omic results provide new evidence for germline mechanisms increasing risk of early leukaemogenesis.
KW - Histone methyltransferases
KW - chromatin remodelling
KW - development
KW - gene expression
KW - hemogenic endothelium
KW - mesoderm
KW - pluripotency
UR - http://www.scopus.com/inward/record.url?scp=85111440286&partnerID=8YFLogxK
U2 - 10.1080/15592294.2021.1954780
DO - 10.1080/15592294.2021.1954780
M3 - Article
C2 - 34304711
AN - SCOPUS:85111440286
SN - 1559-2294
VL - 17
SP - 220
EP - 238
JO - Epigenetics
JF - Epigenetics
IS - 2
ER -